INT57115

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 4.35
Pain Relevance 2.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (NT5E) plasma membrane (NT5E) DNA metabolic process (NT5E)
cytoplasm (NT5E)
Anatomy Link Frequency
brain 1
NT5E (Homo sapiens)
Pain Link Frequency Relevance Heat
Catechol-O-methyltransferase 174 100.00 Very High Very High Very High
induced neuropathy 3 95.40 Very High Very High Very High
agonist 13 95.28 Very High Very High Very High
adenocard 34 95.04 Very High Very High Very High
Dopamine 69 94.28 High High
peripheral neuropathy 2 92.08 High High
headache 5 91.96 High High
Central nervous system 15 90.92 High High
Kinase C 5 89.40 High High
Sciatic nerve 7 84.80 Quite High
Disease Link Frequency Relevance Heat
Neuropathy 8 100.00 Very High Very High Very High
Neuropathic Pain 10 99.32 Very High Very High Very High
Convulsion 5 95.68 Very High Very High Very High
Coma 5 95.16 Very High Very High Very High
Ataxia 3 94.92 High High
Disease 150 93.60 High High
Confusion 1 93.32 High High
Dizziness 2 92.88 High High
Sleep Disorders 1 92.44 High High
Peripheral Neuropathy 2 92.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This effect was called promotion of axonopathies and it was found not to be associated with inhibition of neuropathy target esterase (NTE), the molecular target of OPIDP.
Negative_regulation (inhibition) of NTE associated with neuropathy
1) Confidence 0.57 Published 2005 Journal Chem. Biol. Interact. Section Abstract Doc Link 16243301 Disease Relevance 0.36 Pain Relevance 0.16
Some OPs can also induce a delayed neuropathy which does not involve inhibition of AChE but rather the neuropathy target esterase (NTE) [25,26].
Negative_regulation (inhibition) of NTE associated with neuropathy
2) Confidence 0.10 Published 2008 Journal Environ Health Section Body Doc Link PMC2577708 Disease Relevance 1.29 Pain Relevance 0.24
Moreover, inhibition of ATP degradation via targeted gene deletion or inhibition of CD39 and CD73 has been found to eliminate the cardioprotective effect of preconditioning [32], and increase infarct size [33].
Negative_regulation (inhibition) of CD73
3) Confidence 0.07 Published 2010 Journal BMC Cardiovasc Disord Section Body Doc Link PMC2820435 Disease Relevance 0.63 Pain Relevance 0.47
These findings warrant a discussion about which COMT inhibitor, EN or tolcapone, is
               more suitable for modulating homocysteine synthesis. 
Negative_regulation (inhibitor) of EN associated with catechol-o-methyltransferase
4) Confidence 0.05 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778405 Disease Relevance 0.05 Pain Relevance 0.26
The greater inhibition of S-NTE than P-NTE in vivo contrasts with the observation that S-NTE is less sensitive in vitro.
Negative_regulation (inhibition) of S-NTE
5) Confidence 0.04 Published 1994 Journal Toxicol. Lett. Section Abstract Doc Link 8140588 Disease Relevance 0.38 Pain Relevance 0.20
The highest dose with no observable neuropathic effects (1.5 mg/kg mipafox p.o.) inhibited 33% P-NTE and 55% S-NTE activity.
Negative_regulation (inhibited) of S-NTE associated with neuropathic pain
6) Confidence 0.04 Published 1994 Journal Toxicol. Lett. Section Abstract Doc Link 8140588 Disease Relevance 0.41 Pain Relevance 0.21
An additional negative criterion for tolcapone use is the need for a previous failed
               response to EN or intolerance of intake of other COMT inhibitors.


Negative_regulation (inhibitors) of EN associated with catechol-o-methyltransferase
7) Confidence 0.03 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778405 Disease Relevance 0.76 Pain Relevance 0.31
One must realize that 300 mg LD/CD are not comparable to 300 mg LD/CD/EN,
               since the additional COMT inhibition with EN delivers more LD to the brain and thus
               improves the clinical efficacy of LD.
Negative_regulation (inhibition) of EN in brain associated with catechol-o-methyltransferase
8) Confidence 0.03 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778405 Disease Relevance 0.46 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox